Centre Hospitalier Intercommunal De Cornouaille
- Address
- lock Available on a paid plan
Centre Hospitalier Intercommunal De Cornouaille - Multi-Specialty Clinical Research Center
The Centre Hospitalier Intercommunal De Cornouaille is a comprehensive clinical research institution conducting advanced trials across multiple therapeutic areas. The center demonstrates particular expertise in oncology, nephrology, and infectious disease research, contributing to the development of novel treatment strategies for complex medical conditions.
- Advanced oncology trials including lung cancer (NSCLC with various genetic mutations including KRAS G12C, ROS1 rearrangements, and EGFR alterations), hematologic malignancies (multiple myeloma, lymphomas), and solid tumors (prostate cancer, breast cancer, colorectal cancer, urothelial cancer)
- Chronic kidney disease and hypertension research, focusing on novel therapeutic combinations and disease progression management
- Infectious disease and immunological disorder studies, including prosthetic joint infections, catheter-related bloodstream infections, HIV treatment optimization, and autoimmune conditions such as ANCA vasculitis and systemic sclerosis
- Specialized research in myeloproliferative neoplasms, pulmonary conditions including idiopathic pulmonary fibrosis and severe asthma, and neurological disorders such as multiple sclerosis
The center participates in cutting-edge precision medicine approaches, including biomarker-driven trials utilizing circulating tumor DNA, MRD (minimal residual disease) assessment, and tumor-infiltrating lymphocyte evaluation. Research encompasses both early-phase exploratory studies and large-scale international Phase III randomized controlled trials, with emphasis on immunotherapy combinations, targeted therapies, and personalized treatment strategies across diverse patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 22 therapeutic areas and 15 of 206 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 198 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 31 by active trials.
- 1AstraZeneca AB6active
lock +30 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB12trials
lock +16 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Intercommunal De Cornouaille
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer | Seagen Inc. | Phase III | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 206 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2022-12-02 | 2026-06-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.